



Ecologically-Advanced® Probiotics for Lactose Intolerance from Synbiotic Health.

Bifidobacterium adolescentis iVS-1® Improves Lactose Intolerance

Lactose malabsorption, the inability to digest lactose, affects 70% of the world population, depriving people of the nutritional value and other benefits of dairy products. Recent research has shown that lactose-intolerant individuals can safely consume lactose if their microbiota is enriched with lactase-producing bifidobacteria.

Bifidobacterium adolescentis iVS-1® has more genes for metabolizing lactose (Fig. 1) and outperforms commercial strains at reducing gas production from lactose (Fig. 2). Therefore, we organized a randomized, placebo-controlled clinical trial to test the ability of iVS-1° (one billion CFU/day for 14 days) to improve symptom scores in lactose-intolerant subjects (Fig. 3).




Figure 1. iVS-1® has more genes for metabolizing lactose.




Figure 2. In a pre-clinical model, iVS-1® reduces the gas produced by fecal communities given lactose.




Figure 3. iVS-1[®] showed significant improvements in bloating, flatulence, and fecal urgency, compared to the placebo, in individuals who experienced symptoms during the 42-day clinical trial.



synbiotichealth.com

health@SynbioticHealth.com

Leading with Science®:

Synbiotic Health researches & develops Ecologically Advanced® microbiome ingredients for improved health. Using our novel discovery platforms iVS® and iVE®, Synbiotic Health is pioneering a new category of Synergistic Synbiotics®proprietary select combinations of Ecologically Advanced Probiotics® and prebiotics that change the microbiome to provide documented health benefits.